February 2012 Drug Update Information - Pharmacy Benefits ...

CICLOPIROX/
TOPICAL
PEDIPIROX-4
New
NAIL LACQ/FT
8 %
ANTIFUNGALS
TOPICAL KIT
Combination
DEOD#4
Gruenhaupt, Mark R.Ph. Argus Health Systems, Inc. c2005 Available from: www.argushealth.com [cited January 5, 2012].
Gruenhaupt, Mark R.Ph. Argus Health Systems, Inc. c2005 Available from: www.argushealth.com [cited January 19, 2012].
New Indicatio
ons (Existing Drugs)
Prevnar 13®
FDA Approval to Extend Use of
Prevnar 13®
for Prevention of Pneumococcal Pneumonia and
Invasive Disease in Adults 50 Years and Older
December 30, 2011
Pfizer Inc. announced
that the U. .S. Food and
Drug Administration (FDA) has granted approval
of the Company’s pneumococcal
conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent
Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnarr 13
is indicated for adults 50 years of
age and older for active immunization for the prevention of
pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S.
pneumoniae)
serotypess contained in the vaccine.
Article link: http://www.pfizer.com/news/press_releases/
/pfizer_press_releases.jsp
#guid=20120105006142en&source=RSS_2011&page=11
Source website: http: ://www.pfizer.com
Berinert®
FDA Approval of Expanded Label on Berinert® for Self-administration and
Treatment of
Acute Laryngeal Attacks of Hereditary Angioedema
January
3, 2012
CSL Behring announced that the
U.S. Food and Drug Administrationn (FDA) has
approved a
label expansion for self-administration of Berinert®, C1 Esterase Inhibitor (Human), a
pasteurized, nanofiltered therapy
indicated for the treatment of acute
attacks of hereditary
angioedema (HAE), a rare and potentially fatal genetic disorder. With appropriate training from
a physician, patients can now self-administer
Berinert byy intravenous infusion. As part of the
label expansion, Berinert is now also indicated to treat life-threatening laryngeall HAE attacks, as
well as facial and abdominal attacks.
Article link: http://www.cslbehring.com/news-room/HAE-Berinert-Self-Administration-and-
Laryngeal-Attacks
Source website: http: ://www.cslbehring.com/
FDA News/ /Bulletins/Advisories/Safety Alerts
FDA Drug Safety Communicat
tion: Addition of another concentration of liquid
acetaminophen marketed for infants
[Posted 12/22/11]
The U.S. Food and Drug Administration (FDA) is informing the public that an additional
concentration of liquid acetaminophen marketed for "infants" (160 mg/5 mL) is now available at
local stores. Until now, liquid acetaminophenn marketed for infants was only available in 80
mg/0.8 mL or 80 mg/mL concentrations. This change in the concentration will affect the amount
5